ClinicalTrials.gg
Not yet recruitingNCT07577284Updated Oct 5, 2026

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome

An interventional study of AI chatbot-enabled nurse-led program. and Usual Care in Cardiovascular-kidney-metabolic Syndrome, sponsored by Taipei Medical University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Taipei Medical University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Start date movedEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Metabolic Syndrome with a site in Taiwan — 15 open to participants now, 15 under way, none of them phase 3. Metabolic Syndrome · Taiwan.

Planned enrollment
18th of 40
80 · median 80
Started
2026
with 3 others
No phase
32 of 69
8 open now
Primary completion
2027-07
later than 7 of 14 live
Registered
65th of 69
by date
Lead sponsor
2 of 69
Taipei Medical University

Among the 69 studies in Metabolic Syndrome with a site in Taiwan, this one is the 18th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2026, is one of 32 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 65th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

15 of the 69 studies in Metabolic Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Metabolic Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

This randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 participants will be randomly assigned to either the intervention or control group and followed for 6 months. Participants in the intervention group will complete weekly ePRO assessments through an AI-enabled platform and receive individualized feedback, self-management support, and nurse-led clinical follow-up when indicated. Participants in the control group will receive usual care and complete weekly ePRO assessments through a non-AI platform without automated feedback or structured nurse-led support. Outcomes will be assessed at baseline, 3 months, and 6 months and will include patient-reported health outcomes, patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage.

Read the detailed description

This two-arm, parallel-group randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 adults aged 40 years or older with stage 1 or stage 2 CKM syndrome will be recruited from one tertiary hospital in Northern Taiwan and followed for 6 months. Participants will be randomly assigned in a 1:1 ratio using computer-generated permuted block randomization with randomly varying block sizes of 4 and 6 and allocation concealment.

Participants in the intervention group will receive usual outpatient care plus an AI chatbot-enabled ePRO monitoring and nurse-led self-management intervention. The AI-enabled platform will support weekly ePRO monitoring, individualized feedback, self-management support, and risk identification. Nurses will review clinically significant alerts and provide individualized support, care coordination, and clinical escalation when indicated.

Participants in the control group will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or nurse-led follow-up based on their weekly ePRO responses.

Primary outcomes include the seven PROMIS-29 domain-specific T-scores and the 0-10 Pain Intensity score. Secondary outcomes include patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage. Patient-reported health outcomes, patient activation, health literacy, and CKM syndrome stage will be assessed at baseline, 3 months, and 6 months, while healthcare utilization will be assessed prospectively over the 6-month follow-up period, with data collected at 3 and 6 months and updated through interim participant reports.

03

Conditions studied

  • Cardiovascular-kidney-metabolic Syndrome

Browse trials for

Keywords

  • artificial intelligence
  • cardiovascular-kidney-metabolic syndrome
  • electronic patient-reported outcomes
  • nurse-led care
  • self-management
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

***Inclusion Criteria***

  • Adults aged ≥40 years
  • Meet the criteria for stage 1 or stage 2 cardiovascular-kidney-metabolic (CKM) syndrome
  • Receive regular outpatient care at the study hospital
  • Able to communicate in Chinese
  • Able to provide written and complete the required study assessments
  • Have access to a smartphone or tablet compatible with the study ePRO platform

***Exclusion Criteria***

  • Meet the criteria for stage 3 or stage 4 CKM syndrome, including known subclinical cardiovascular disease, a stage 3 cardiovascular risk equivalent, or established clinical cardiovascular disease
  • Have kidney failure requiring chronic kidney replacement therapy
  • Have a terminal illness with a of \<6 months
  • Have cognitive impairment that, in the judgment of the treating physician or research team, precludes informed consent or meaningful participation in the intervention
  • Are currently participating in another interventional study that could substantially influence the study outcomes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management

    Participants will receive usual outpatient care plus a 6-month AI chatbot-enabled ePRO monitoring and nurse-led self-management program, including weekly ePRO assessments, individualized feedback, self-management support, risk alerts, and nurse-led follow-up when indicated.

    Other: AI chatbot-enabled nurse-led program.

  • Other
    Control group

    Participants will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or structured nurse-led support based on their weekly ePRO responses.

    Other: Usual Care

Interventions

  • OtherAI chatbot-enabled nurse-led program.

    Participants in the intervention group will receive a six-month nurse-led, AI chatbot-enabled symptom monitoring and self-management program integrating weekly ePRO assessments. The intervention begins with a structured nurse-led intake session including CKM assessment, symptom review, goal setting, and training on chatbot use. Participants complete weekly PROMIS-29 v2.1 assessments via a smartphone-based chatbot, which provides automated, rule-based feedback, self-management guidance, and motivational prompts. A risk-stratification algorithm generates alerts when symptom deterioration is detected. Nurses review alerts daily and provide follow-up via messaging, teleconsultation, or referral depending on severity, with same-day escalation for high-risk symptoms.

  • OtherUsual Care

    Usual care based on standard outpatient follow-up, without access to the AI chatbot or nurse-led coordination

06

What researchers measure

Primary outcomes

  1. PROMIS-29 v2.1 Domain-Specific T-Scores and Pain Intensity

    The PROMIS-29 v2.1 Traditional Chinese version will be used to assess seven health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Each domain contains four items and will be scored separately and converted to standardized T-scores with a reference-population mean of 50 and standard deviation of 10. Higher T-scores indicate greater symptom burden for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, whereas higher T-scores indicate better health for Physical Function and Ability to Participate in Social Roles and Activities. Pain Intensity will be assessed separately using a single 0-10 numeric rating scale, with higher scores indicating greater pain intensity.

    Time frame: Baseline, 3 months, and 6 months

Secondary outcomes

  1. Patient Activation Measure-13 (PAM-13)

    Patient activation will be assessed using the 13-item Patient Activation Measure (PAM-13), which evaluates individuals' knowledge, skills, and confidence in managing their health. Items are rated on a 5-point response scale, including a "not applicable" option. Raw scores are converted to a 0-100 scale, with higher scores indicating greater patient activation.

    Time frame: Baseline, 3 months, and 6 months.

  2. Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ)

    Health literacy will be assessed using the 20-item Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ), which covers five domains: obtaining, understanding, evaluating, and applying health information, as well as communication and interaction. Each item is rated on a 4-point scale from very difficult to very easy. Scores are transformed to a 0-50 scale, with higher scores indicating better health literacy. Scores are categorized as insufficient (0-25), limited (\>25-33), sufficient (\>33-42), and excellent (\>42-50).

    Time frame: Baseline, 3 months, and 6 months.

  3. Healthcare Utilization

    Healthcare utilization will be assessed prospectively based on participant self-report of the number of emergency department visits and hospitalizations occurring during each follow-up interval. Participants will also be encouraged to report such events through the study platform between scheduled assessments.

    Time frame: Enrollment to 3 months and 3 months to 6 months

  4. Change in CKM Syndrome Stage

    CKM syndrome stage will be assessed using available clinical and laboratory information and participant-reported updates. Changes from baseline will be categorized as progression to a more advanced CKM syndrome stage or improvement to a lower stage.

    Time frame: Baseline, 3 months, and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be publicly shared due to ethical and privacy considerations. However, de-identified datasets may be made available to qualified researchers upon reasonable request after publication, subject to approval by the corresponding author and the Institutional Review Board (IRB) of Taipei Medical University. Data sharing will comply with institutional policies and applicable data protection regulations

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 9 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Oct 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 11, 2026
StartEst.
Oct 1, 2026was May 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 30, 2026→Oct 1, 2026
Oct 5, 2026
Enrollment
72→80
Oct 5, 2026
Eligibility
Criteria largely rewritten (18 changes)
What changed in the criteria
  • Added***Inclusion Criteria***
  • EditedAdults aged ≥40 years
  • AddedMeet the criteria for stage 1 or stage 2 cardiovascular-kidney-metabolic (CKM) syndrome
  • AddedReceive regular outpatient care at the study hospital
  • EditedAble to communicate in Mandarin/Taiwanese, andChinese
  • AddedAble to provide written informed consent and complete the required study assessments
  • EditedHavingHave access to a smartphone/ or tablet compatible with the study ePRO platform
  • Added***Exclusion Criteria***
  • AddedMeet the criteria for stage 3 or stage 4 CKM syndrome, including known subclinical cardiovascular disease, a stage 3 cardiovascular risk equivalent, or established clinical cardiovascular disease
  • AddedHave kidney failure requiring chronic kidney replacement therapy
  • EditedHave a terminal illness (with a life expectancy of <6 months life expectancy)
  • AddedHave cognitive impairment that, in the judgment of the treating physician or research team, precludes informed consent or meaningful participation in the intervention
  • AddedAre currently participating in another interventional study that could substantially influence the study outcomes
Inclusion criteria
  • RemovedClassified as having stage CKM syndrome (stage 1-2)
  • RemovedReceiving outpatient care
Exclusion criteria
  • RemovedEnd-stage kidney disease requiring dialysis or are listed for kidney transplantation
  • RemovedHave significant cognitive impairment
  • RemovedCurrently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity
Oct 5, 2026
Interventions
Arm changed AI chatbot-enabled nurse-led program→AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPROMIS-29 v2.1 Domain-Specific T-Scores and Pain IntensityTime frame: Baseline, 3 months, and 6 months after randomization → Baseline, 3 months, and 6 months
Oct 5, 2026
Secondary outcomes
4 added, 4 removed
What changed in the outcomes
  • AddedPatient Activation Measure-13 (PAM-13)Time frame: Baseline, 3 months, and 6 months.
  • AddedMandarin Multidimensional Health Literacy Questionnaire (MMHLQ)Time frame: Baseline, 3 months, and 6 months.
  • AddedHealthcare UtilizationTime frame: Enrollment to 3 months and 3 months to 6 months
  • AddedChange in CKM Syndrome StageTime frame: Baseline, 3 months, and 6 months
  • RemovedPAM-13Time frame: Baseline, 3 months, and 6 months.
  • RemovedMMHLQTime frame: Baseline, 3 months, and 6 months.
  • RemovedNumber of emergency department visitTime frame: Baseline, 3 months, and 6 months.
  • RemovedHospitalizationsTime frame: Baseline, 3 months, and 6 months
Oct 5, 2026
Contact
Study contact changed: p•••@tmu.edu.tw · •••1661→p•••@tmu.edu.tw · •••1661. See the current contact
Oct 5, 2026
Title
AI Chatbot-Enabled ePRO Symptom Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date May 30, 2026→Oct 1, 2026
    Enrollment 72→80
    Eligibility Criteria largely rewritten (18 changes)
    What changed in the criteria
    • Added***Inclusion Criteria***
    • EditedAdults aged ≥40 years
    • AddedMeet the criteria for stage 1 or stage 2 cardiovascular-kidney-metabolic (CKM) syndrome
    • AddedReceive regular outpatient care at the study hospital
    • EditedAble to communicate in Mandarin/Taiwanese, andChinese
    • AddedAble to provide written informed consent and complete the required study assessments
    • EditedHavingHave access to a smartphone/ or tablet compatible with the study ePRO platform
    • Added***Exclusion Criteria***
    • AddedMeet the criteria for stage 3 or stage 4 CKM syndrome, including known subclinical cardiovascular disease, a stage 3 cardiovascular risk equivalent, or established clinical cardiovascular disease
    • AddedHave kidney failure requiring chronic kidney replacement therapy
    • EditedHave a terminal illness (with a life expectancy of <6 months life expectancy)
    • AddedHave cognitive impairment that, in the judgment of the treating physician or research team, precludes informed consent or meaningful participation in the intervention
    • AddedAre currently participating in another interventional study that could substantially influence the study outcomes
    Inclusion criteria
    • RemovedClassified as having stage CKM syndrome (stage 1-2)
    • RemovedReceiving outpatient care
    Exclusion criteria
    • RemovedEnd-stage kidney disease requiring dialysis or are listed for kidney transplantation
    • RemovedHave significant cognitive impairment
    • RemovedCurrently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPROMIS-29 v2.1 Domain-Specific T-Scores and Pain IntensityTime frame: Baseline, 3 months, and 6 months after randomization → Baseline, 3 months, and 6 months
    Secondary outcomes 4 added, 4 removed
    What changed in the outcomes
    • AddedPatient Activation Measure-13 (PAM-13)Time frame: Baseline, 3 months, and 6 months.
    • AddedMandarin Multidimensional Health Literacy Questionnaire (MMHLQ)Time frame: Baseline, 3 months, and 6 months.
    • AddedHealthcare UtilizationTime frame: Enrollment to 3 months and 3 months to 6 months
    • AddedChange in CKM Syndrome StageTime frame: Baseline, 3 months, and 6 months
    • RemovedPAM-13Time frame: Baseline, 3 months, and 6 months.
    • RemovedMMHLQTime frame: Baseline, 3 months, and 6 months.
    • RemovedNumber of emergency department visitTime frame: Baseline, 3 months, and 6 months.
    • RemovedHospitalizationsTime frame: Baseline, 3 months, and 6 months
    Interventions Arm changed AI chatbot-enabled nurse-led program→AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management
    Contact Study contact changed: p•••@tmu.edu.tw · •••1661→p•••@tmu.edu.tw · •••1661. See the current contact
    Title AI Chatbot-Enabled ePRO Symptom Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome
    + 4 other changes: index terms, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577284
Responsible party
Pei-Shan, Tsai (Principal Investigator, Taipei Medical University) — Principal investigator
First posted
May 11, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Pei-Shan Tsai, PhD in Nursing
Contact
ptsai@tmu.edu.tw
+886 2 2736 1661 ext. 27709

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion